Sogroya 10 Mg/1.5 Ml Pre-Filled Pen

Product Description:

• Sogroya 10 mg/1.5 ml solution for injection in pre-filled pen.


• One mL of solution contains 6.7 mg of somapacitan.


• Each pre-filled pen contains 10 mg of somapacitan in 1.5 mL solution.


• Produced by recombinant DNA technology in Escherichia coli followed by attachment of an albumin binding moiety. 


• Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD).

Sogroya contains the active substance somapacitan:

• A long acting version of the natural growth hormone produced by the body with a single amino acid substitution.


• growth hormone regulates the composition of fat, muscle and bone in adults.


• The active substance in sogroya is made by 'recombinant DNA technology', meaning from cells that have received a gene (DNA) that makes them produce growth hormone.


• In sogroya, a small sidechain has been attached to the growth hormone which links sogroya to the protein (albumin) naturally found in the blood to slow down its removal from the body, allowing the medicine to be given less often.


• sogroya is used to treat adults who have growth hormone deficiency.


• Your doctor will evaluate based on your response to sogroya, if you should continue your treatment with sogroya a year after starting with this medicine.

How To Use:

• Sogroya comes in one strength. Your healthcare provider will prescribe the dose that is right for you.


• Your healthcare provider will show you how to inject Sogroya.


• Use Sogroya exactly as your healthcare provider tells you to.


• Use Sogroya one time each week.


• If you miss a dose of Sogroya, take the missed dose as soon as possible within 3 days (72 hours) after the missed dose.


• If more than 3 days (72 hours) have passed, skip the missed dose and take your next dose on the regularly scheduled day.


• Sogroya pens are for use by one person only.


• Do not share your Sogroya pens and needles with another person, even if the needle has been changed.


• You may give another person an infection or get an infection from them.

Warnings And Precautions:

Do not use Sogroya if:

• You are allergic to somapacitan or any of the other ingredients of this medicine.


• You have a benign or malignant tumour which is growing.


• You must have completed your antitumour treatment before you start your sogroya treatment.


• Sogroya must be stopped if the tumour grows.


• You have recently had open heart surgery or abdominal surgery or multiple accidental injury, severe breathing problems or similar condition.


• Hypersensitivity to the active substance.


• Somapacitan must not be used when there is any evidence of activity of a tumour.


• Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting somapacitan therapy.


• Treatment should be discontinued if there is evidence of tumour growth.


• Patients with acute critical illness suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions must not be treated with somapacitan (regarding patients undergoing substitution therapy).

Ingredients:

• Sogroya 10 mg/1.5 ml solution for injection in pre-filled pen.

Product Details: